Literature DB >> 3723234

Doxapram in the treatment of idiopathic apnea of prematurity: desirable dosage and serum concentrations.

F Hayakawa, S Hakamada, K Kuno, T Nakashima, Y Miyachi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3723234     DOI： 10.1016/s0022-3476(86)80594-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  10 in total

1.  Serum doxapram and respiratory neuromuscular drive in normal man.

Authors:  S Okubo; K Konno; T Ishizaki; T Suganuma; T Takubo; T Takizawa; M Tanaka
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 2.  Doxapram Treatment for Apnea of Prematurity: A Systematic Review.

Authors:  Roseanne J S Vliegenthart; Christine H Ten Hove; Wes Onland; Anton H L C van Kaam
Journal:  Neonatology       Date:  2016-10-20       Impact factor: 4.035

Review 3.  Risks and benefits of therapies for apnoea in premature infants.

Authors:  J M Hascoet; I Hamon; M J Boutroy
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

Review 4.  Treatment of apnea of prematurity.

Authors:  Varsha Bhatt-Mehta; Robert E Schumacher
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

5.  Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial.

Authors:  E Greze; M Benard; I Hamon; C Casper; F E Haddad; M-J Boutroy; J-M Hascoët
Journal:  Paediatr Drugs       Date:  2016-12       Impact factor: 3.022

6.  Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea.

Authors:  Yuki Ogawa; Mitsuru Irikura; Yuka Kobaru; Mayu Tomiyasu; Yoshie Kochiyama; Mamiko Uriu; Yoichi Ishitsuka; Yuki Kondo; Eiji Yukawa; Noboru Kamada; Hitoshi Ohno; Toshio Yamazaki; Tetsumi Irie
Journal:  Eur J Pediatr       Date:  2014-09-25       Impact factor: 3.183

Review 7.  Cardiorespiratory events in preterm infants: interventions and consequences.

Authors:  J M Di Fiore; C F Poets; E Gauda; R J Martin; P MacFarlane
Journal:  J Perinatol       Date:  2015-11-19       Impact factor: 2.521

8.  Doxapram only slightly reduces the shivering threshold in healthy volunteers.

Authors:  Ryu Komatsu; Papiya Sengupta; Grigory Cherynak; Anupama Wadhwa; Daniel I Sessler; Jin Liu; Harrell E Hurst; Rainer Lenhardt
Journal:  Anesth Analg       Date:  2005-11       Impact factor: 6.627

9.  Doxapram use for apnoea of prematurity in neonatal intensive care.

Authors:  S A Prins; S J A Pans; M M van Weissenbruch; F J Walther; S H P Simons
Journal:  Int J Pediatr       Date:  2013-11-26

10.  Simultaneous quantification of fentanyl, sufentanil, cefazolin, doxapram and keto-doxapram in plasma using liquid chromatography-tandem mass spectrometry.

Authors:  Robert B Flint; Soma Bahmany; Bart C H van der Nagel; Birgit C P Koch
Journal:  Biomed Chromatogr       Date:  2018-06-12       Impact factor: 1.902
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.